NKNadine Kuniss

Nadine Kuniss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadine Kuniss has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Christof Kloos

    Department for Internal Medicine III Jena University Hospital Jena Germany

    12 shared publications
  • Guido Kramer

    Universitätsklinikum Jena, Klinik für Innere Medizin III, FB Endokrinologie und Stoffwechselerkrankungen, Jena, Germany; Universitätsklinikum Jena, Jena, Germany

    11 shared publications
  • Gunter Wolf

    Department for Internal Medicine III Jena University Hospital Jena Germany

    7 shared publications
  • Ulrich A. Müller

    Outpatient healthcare centre Dr. med. Kielstein, Erfurt, Germany

    6 shared publications
  • Nicolle Müller

    Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine III, Jena University Hospital, Jena, Germany

    5 shared publications
  • Nicolle Müller

    Department of Internal Medicine III, University Hospital Jena, 07743 Jena, Germany

    5 shared publications

Latest Publications

  • Open Access

    How do hypoglycaemias affect the everyday life of people with diabetes and are they able to treat them adequately?

    by Nicolle Müller, Christiane Kellner, Sebastian Schmidt, Nadine Kuniß, Gunter Wolf, Christof Kloos

    Aims: To investigate whether people with type 1 and type 2 diabetes respond adequately to hypoglycaemia symptoms after participating in a treatment and teaching programme. Additionally, it explored how hypoglycaemia impacts patients' everyday life and the differences between individuals with and without impaired awareness of hypoglycaemia (IAH).Methods: This cross‐sectional study included 340 adult participant with type 1 (n = 156) or type 2 diabetes (n = 184) undergoing insulin therapy at the University Hospital Jena. Participants completed validated questionnaires and participated in structured interviews about hypoglycaemia. Awareness of hypoglycaemia was measured using the Gold Score, and diabetes distress with the PAID Scale (PAID Score 0–100, the higher the score the higher the distress).Results: 23.8% of the participants treated hypoglycaemia adequately (type 1 diabetes 27.6% vs. type 2 diabetes 24.7%; p = 0.606). Significantly more people without IAH‐treated hypoglycaemia adequately in type 2 (27.9% vs. 10.3%; p = 0.047) but not in type 1 diabetes (28.6% vs. 23.1%; p = 0.568). Hypoglycaemia altered daily routines for 26.2% of participants, particularly those with type 1 diabetes (type 1 diabetes 37.3% vs. type 2 diabetes 20.1%; p = 0.001). People with type 1 and type 2 diabetes reporting changes in daily routines had higher diabetes distress scores (PAID: 22.3 ± 16.0 vs. 13.8 ± 13.5; p < 0.001). Fear of hypoglycaemia was associated with higher HbA1c values due to people accepting elevated blood glucose levels.Conclusions: Despite education programmes, the majority of participants do not treat hypoglycaemia adequately. Hypoglycaemic events significantly impact daily life and are associated with increased diabetes‐related distress, especially in those with IAH.


  • Open Access

    A Randomized Controlled Trial to Assess the Feasibility and Practicability of an Oatmeal Intervention in Individuals with Type 2 Diabetes: A Pilot Study in the Outpatient Sector

    by Michél Fiedler, Nicolle Müller, Christof Kloos, Guido Kramer, Christiane Kellner, Sebastian Schmidt, Gunter Wolf, Nadine Kuniß

    Background/Objectives: The aim of this study was to investigate the feasibility and practicability of repeated three-day sequences of a hypocaloric oat-based nutrition intervention (OI) in insulin-treated outpatients with type 2 diabetes and severe insulin resistance. Methods: A randomized, two-armed pilot study was conducted with three months of intervention and three months follow-up with 17 participants with insulin resistance (≥1 IU/kg body weight). Group A (n = 10) performed one sequence of OI; Group B (n = 7) performed two sequences monthly. A sequence was 3 consecutive days of oat consumption with approximately 800 kcal/d. The main objective was to assess feasibility (≥70% completers) and practicability regarding performance aspects. Biomedical parameters such as HbA1 c were observed. To evaluate the state of health, a standardized questionnaire was used (EQ-5 D). Results: OI was feasible (13/17 completer participants (76.5%): 70.0% Group A, 85.7% Group B). Individually perceived practicability was reported as good by 10/16 participants (62.5%). Total insulin dosage decreased from 138 ± 35 IU at baseline to 126 ± 42 IU after OI (p = 0.04) and 127 ± 42 IU after follow-up (p = 0.05). HbA1 c was lower after OI (−0.3 ± 0.1%; p = 0.01) in all participants. Participants in Group B tended to have greater reductions in insulin (Δ−19 IU vs. Δ−4 IU; p = 0.42) and weight loss (Δ−2.8 kg vs. Δ−0.2 kg; p = 0.65) after follow-up. Severe hypoglycemia was not observed. EQ-5 D increase not significantly after follow-up (57.2 ± 24.0% vs. 64.7 ± 21.5%; p = 0.21). Conclusions: The feasibility and practicability of OI in outpatients were demonstrated. OI frequency appears to correlate with insulin reduction and weight loss. Proper insulin dose adaptation during OI is necessary. Presumably, repeated OIs are required for substantial beneficial metabolic effects.


  • Assessing fear of complications in people with type 1 and type 2 diabetes with the Fear of Diabetes Complications Questionnaire.

    by Andreas Schmitt, Dominic Ehrmann, Nadine Kuniss, Nicolle Müller, Bernhard Kulzer, Norbert Hermanns

    Objective: Fear of diabetes complications (FDC) is a common source of emotional distress in people with diabetes across types and treatments and may affect health outcomes. To assess FDC, the Fear of Diabetes Complications Questionnaire (FDCQ) was developed. This study evaluates the FDCQ's German version in people with type 1 diabetes (T1D) and type 2 diabetes (T2D). Method: A German version of the FDCQ was developed and administered as part of four different studies sampling people with T1D and T2D. Measurement properties were evaluated across studies using factor analyses, reliability estimates, and associations of the measure within a network of variables. A cutoff criterion for elevated FDC was derived. A short form scale was also developed. Results: High reliability and validity were supported. FDC as measured by the FDCQ was independently associated with higher diabetes distress and depressive symptoms. A cut-off score for elevated FDC was set at = 30 in the 15-item FDCQ. Elevated FDCQ scores were detected in 36% of participants in secondary diabetes care and up to 46% of those in tertiary care. Conclusions: FDC is prevalent in people with T1D and T2D and associated with diabetes distress and depressive symptoms. The FDCQ is a reliable and valid tool for assessing FDC in research and practice. It may help identify persons in need of tailored education and care and monitor effects following treatment.


  • Open Access

    Choosing an insulin injector by a structured, pharmaceutical-neutral curriculum via an informed shared decision-making process in 349 insulin-naive patients with diabetes mellitus

    by Bernardo Mertes, Sybille Gödde, Christof Kloos, Nadine Kuniß

    Background: The national guideline for diabetes type 2 claims to involve patients in their decision-making on therapy. Unfortunately, no structured, pharmaceutical-neutral curriculum is available to guide patients in this shared decision-making (SDM) process regarding the insulin injector. The aim of the study was to evaluate which injector patients chose after SDM process and the reasons for their choice. Methods: We developed a curriculum for a SDM process to choose an insulin injector for insulin-naive patients with diabetes mellitus, which took place immediately before the start of the initial treatment with insulin. It was conducted by a physician or diabetes educator with no conflicts of interest. All available human short-acting disposable insulin injectors (A, B and C) were handed out for try-out accompanied by individual counselling. The patients selected their injector of choice and were asked immediately afterwards about the criteria for their selection. Results: 349 consecutive patients (94% diabetes type 2; age 58.6 + 13.4y; HbA1c 10.4 + 2.1%) were included. Patients choose Injector A in 10.0%, B in 61.9% and C in 28.1%. Criteria for selection were: design (41.8%), general impression (23.5%), dose window (7.7%), dose selection dial (7.4%), most practical (6.6%) and other (13%). Selection of a specific injector was not associated with age, diabetes type, diabetes duration, BMI, HbA1c, presence of concomitant diseases, retinopathy, neuropathy, diabetic foot or physician/diabetes educator. Discussion: Insulin-naive patients with diabetes mellitus chose their own insulin injector within a newly developed structured SDM process to meet the national guideline. Main selection criteria were design and practicability.

  • In einer Kohorte von 1006 Menschen mit Typ-2-Diabetes und Versagen oraler Antidiabetika senkt die Einstellung auf NPH-Insulin zur Nacht mit 0,1 IE/kg den HbA1c-Wert ohne Gewichtszunahme und Hypoglykämien

    by Bernardo Mertes, Sybille Gödde, Til Uebel, Günther Egidi, Guido Kramer, Petra Baseler, Hafida El Bali, Philine Junius, Nadine Kuniß

    Hintergrund NPH-Insulin zur Nacht (NZN) wird in der aktualisierten NVL und in einer neuen DMP-Anforderungs-Richtlinie des GB-A empfohlen, wenn mit oralen Antidiabetika (OAD) das HbA1c-Therapieziel verfehlt wird. In Leitlinien werden als NZN-Start-Dosis 0,1-0,3 IE/kg Körpergewicht angegeben. Systematische Untersuchungen zur NZN-Start-Dosis liegen jedoch nicht vor. Fragestellung Ermittlung der NZN-Start-Dosis bei OAD-Versagen und Evaluation der NZN-Ersteinstellung im Rahmen einer strukturierten Schulung und Behandlung durch Nachuntersuchung von HbA1c-Wert, Körpergewicht und Hypoglykämien. Methoden Eine Kohorte von 1006 Menschen mit Typ-2-Diabetes (63% männlich, Alter 59,5±11,5 Jahre, Gewicht 91,8±19,1 kg, BMI 31,4±5,9 kg/m², Diabetesdauer 7,5±5,7 Jahre, HbA1c 8,6±1,1%) und OAD-Versagen (Anzahl verschiedener OAD-Substanzklassen 2,1±0,3/Patient:in) wurde im Rahmen einer strukturierten Schulung erstmalig auf NZN eingestellt (Programm für bedarfsgerechte Insulintherapie von Grüßer und Jörgens). Die Behandlung dauerte 20,2±24,9 Tage. Dabei wurde ab einer Dosis von 8 IE NPH-Insulin der Blutzuckerverlauf während der Nacht gemessen und die Dosis ggf. angepasst. Die OAD-Kombination wurde belassen. Ergebnisse Die NZN-Dosis betrug am Ende der Behandlung 9,8±2,7 IE, was 0,11±0,03 IE/kg Körpergewicht entspricht. Die Evaluation erfolgte nach 21±18 Wochen. Dabei wurden 96% der Patient:inen nachuntersucht. HbA1c-Wert und Körpergewicht reduzierten sich auf 7,5±1,0% (p < 0,001) und 91,0±18,8kg (p < 0,001). Schwere oder symptomatische Hypoglykämien kamen nicht vor. Diskussion In der Kohorte zeigte sich 21 Wochen nach Einstellung mit 0,1 IE NZN/kg Körpergewicht eine statistisch signifikante und klinisch relevante Besserung von HbA1c-Wert und Körpergewicht. Hypoglykämien traten nicht auf. Dies kann an der niedrigen, aber effektiven, NZN-Dosis gelegen haben. Eine höhere Start-Dosis scheint nicht erforderlich zu sein, kann aber das Risiko für nächtliche Hypoglykämien erhöhen. Es bestehen keinerlei Interessenkonflikte, diese Arbeit wurde ausschließlich mit privaten Mitteln finanziert. Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Umstellung auf ein Hybrid-Closed-Loop-System – Veränderungen der Stoffwechseleinstellung bei Menschen mit Diabetes mellitus Typ 1 in der Routineversorgung

    by Guido Kramer, Nadine Kuniß, Gunter Wolf, Christof Kloos

    Hintergrund Das Ziel dieser Untersuchung war zu analysieren, ob sich nach Umstellung auf ein Hybrid-Closed-Loop-System die Stoffwechseleinstellung bei Menschen mit Diabetes Typ 1 in der Routineversorgung verbessert. Methodik In einer Hochschulpoliklinik für Endokrinologie und Stoffwechselerkrankungen wurden alle Patienten (n=29, Alter 44,7J; Diabetesdauer 22,9J; weiblich 55,2%; CSII vor Start des Systems n=82,8%), welche mindestens zwei Monate ein Hybrid-Closed-Loop-System getragen haben, eingeschlossen. Alle Studienteilnehmer verwendeten vor Umstellung (T0) auf das System sowie zur letzten ambulanten Vorstellung (T1) ein CGM-System. Die Qualität der Glukoseeinstellung wurde mittels „Time in Range“ (TiR, 3,9-10 mmol/l bzw. 70-180 mg/dl, Ziel > 70%), „Time above Range“ (TaR, > 10,0 mml/l bzw. 180 mg/dl, Ziel<25%) sowie „Time below Range“ (TbR,<3,9 mmol/l bzw. 70mg/dl, Ziel<5%) der letzten zwei Wochen beurteilt. Ergebnisse Es waren alle Hersteller vertreten. Die mittlere Tragedauer betrug 0,7±0,5 Jahre. Nicht schwere Hypoglykämien/Woche (1,8±2,2 vs. 0,5±0,8, p=0,004) sowie der HbA1c-Wert (8,5±1,0 vs. 7,5±0,9%, p<0,001) reduzierten sich signifikant zwischen T0 und T1. TiR (41,9±18,8 vs. 70,1±12,0%, p<0,001), TaR (54,2±18,4 vs. 28±12%, p<0,001) sowie TbR (3,4±4,1 vs. 0,9±1,1%, p=0,001) verbesserten sich ebenfalls signifikant im Nachuntersuchungszeitraum (T0 vs. T1). Die Tagesinsulindosis (47,4±25,5 vs. 45,3±20,4 IE/Tag, p=0,287) sowie der BMI (26,5±4,6 vs. 26,6±4,4 kg/m2, p=0,756) waren vergleichbar. Schwere Hypoglykämien traten weder 1 Jahr vor T0 noch innerhalb der Tragedauer auf. Schlussfolgerung Die Umstellung auf ein Hybrid-Closed-Loop-System verbessert die glykämische Kontrolle signifikant (TiR und HbA1c-Wert) und führte zu weniger leichten Hypoglykämien und geringerer TbR. Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Umstellung auf ein Hybrid-Closed-Loop-System – Veränderungen psychosozialer Parameter bei Menschen mit Diabetes mellitus Typ 1 im ambulanten Setting

    by Guido Kramer, Nadine Kuniß, Gunter Wolf, Christof Kloos

    Hintergrund Das Ziel dieser Untersuchung war zu analysieren, ob sich nach Umstellung auf ein Hybrid-Closed-Loop-System psychosoziale Parameter (z.B. Behandlungszufriedenheit, Wohlbefinden) bei Menschen mit Diabetes Typ 1 ändern. Methodik In einer Hochschulpoliklinik für Endokrinologie und Stoffwechselerkrankungen wurden alle Patienten, welche mindestens zwei Monate ein Hybrid-Closed-Loop-System getragen haben, in die Untersuchung eingeschlossen (n=29, Alter 44,7J; Diabetesdauer 22,9J; weiblich 55,2%; CSII vor Start des Systems n=82,8%). Alle Teilnehmer wurden direkt vor Umstellung (T0) sowie bei der letzten ambulanten Konsultation (T1) mittels standardisierter Fragebögen befragt: PAID-Fragebogen (T0 und T1, Score 0-100: je höher der PAID-Score, desto höher die Belastung durch den Diabetes), WHO-5-Fragebogen (T0 und T1, WHO-5-Score 0-25: je höher der Score, desto höher das Wohlbefinden), „Diabetes Treatment Satisfaction Questionnaire status“ (T0, DTSQs-Score 0-36: je höher der Score, desto höher die Behandlungszufriedenheit). Die Änderung der Behandlungszufriedenheit zu T1 wurde mittels des „Diabetes Treatment Satisfaction Questionnaire chance“ bewertet [DTSQc-Score -18 (= maximale Verschlechterung) bis +18 (= maximale Verbesserung der Behandlungszufriedenheit)]. Ergebnisse Es waren alle Hersteller vertreten. Die mittlere Tragedauer betrug 0,7±0,5 Jahre. Diabetesbezogene Belastungen reduzierten sich signifikant nach Umstellung auf ein Hybrid-Closed-Loop-System (PAID-Score: 19,1±13,6 vs. 14,5±10,2, p=0,011). Das allgemeine Wohlbefinden erhöhte sich zwischen T0 und T1 (16,7±4,5 vs. 19,4±2,6; p=0,003). Die diabetesbezogene Behandlungszufriedenheit zu T0 betrug im Mittel 26,2±7,7. Zum Zeitpunkt der Nachuntersuchung (T1) nahm die Behandlungszufriedenheit mit +15,7±2,1 (DTSQc) deutlich zu. Schlussfolgerung Die Umstellung auf ein Hybrid-Closed-Loop-System ist nach circa 8 Monaten mit einer Erhöhung des allgemeinen Wohlbefindens und der diabetesbezogenen Behandlungszufriedenheit sowie einer Reduktion diabetesbezogener Belastungen assoziiert. Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Metabolic control and hypoglycaemia in people with type 1 diabetes: insulin pump therapy vs. intensified insulin therapy in an unselected cohort in routine care

    by Guido Kramer, Christof Kloos, Ulrich A. Müller, Gunter Wolf, Nadine Kuniss

    Aims: The aim of this study was to compare individuals with type 1 diabetes with continuous subcutaneous insulin infusion (CSII) and intensified insulin therapy (ICT) in routine care regarding metabolic control and treatment satisfaction. Methods: Individuals with type 1 diabetes (CSII n = 74; ICT n = 163) were analysed regarding metabolic control, frequency of hypoglycaemia and treatment satisfaction (DTSQs range 0–36). Results: Individuals with CSII (duration of CSII: 14.1 ± 7.2 years) were younger (51.1 ± 15.8 vs. 56.2 ± 16.2 years, p = 0.023), had longer diabetes duration (28.7 ± 12.4 vs. 24.6 ± 14.3 years, p = 0.033), lower insulin dosage (0.6 ± 0.2 vs. 0.7 ± 0.4 IU/kg, p = 0.004), used more frequently short-acting analogue insulin (90.5% vs. 48.5%, p < 0.001) and flash/continuous glucose monitoring (50.0% vs. 31.9%, p = 0.009) than people with ICT. HbA1c was similar between CSII and ICT (7.1 ± 0.8%/54.4 ± 9.1 mmol/mol vs. 7.2 ± 1.0%/55.7 ± 10.9 mmol/mol, p = 0.353). Individuals with CSII had higher frequency of non-severe hypoglycaemia per week (in people with blood glucose monitoring: 1.9 ± 1.7 vs. 1.2 ± 1.6, p = 0.014; in people with flash/continuous glucose monitoring: 3.3 ± 2.2 vs. 2.1 ± 2.0, p = 0.006). Prevalence of polyneuropathy (18.9% vs. 38.0%, p = 0.004) and systolic blood pressure (138.0 ± 16.4 vs. 143.9 ± 17.1 mmHg, p = 0.014) was lower in CSII. Satisfaction with diabetes treatment (26.7 ± 7.3 vs. 26.0 ± 6.8, p = 0.600) did not differ between CSII and ICT. Conclusions: CSII and ICT yielded comparable metabolic control and treatment satisfaction but CSII was associated with higher incidence of non-severe hypoglycaemia and lower insulin dosage.


  • Ernährung und Bewegung

    by Nadine Kuniß, Harm Hammer

  • Open Access

    Diabetes related distress is high in inpatients with diabetes

    by Nadine Kuniss, Guido Kramer, Ulrich A. Müller, Gunter Wolf, Christof Kloos

    Objective: The aim of the present study was to assess diabetes-related distress in inpatients and its association with metabolic control in people with diabetes type 1 (DM1) and type 2 (DM2). Research design and methods: In a cross-sectional study, 107 inpatients with DM1 (age 45.9 years, diabetes duration 18.7 years, HbA1c 8.4%/67.8 mmol/mol) and 109 with DM2 (age 62.0 years, diabetes duration 16.2 years, HbA1c 8.9%/74.3 mmol/mol) from a University department for endocrinology and metabolic diseases (Germany) were included over 2 years. Diabetes-related distress was assessed with the PAID questionnaire (range 0–100, higher scores imply higher diabetes-related distress, cut-off ≥ 40). The PAID questionnaire was completed by 214 of 216 participants. Results: Fifty-one of 214 individuals (23.8%) showed high distress (PAID score ≥ 40). The mean PAID score was 28.1 ± 17.5 in all participants with no difference between DM1 and DM2 (28.1 ± 17.4 vs. 26.2 ± 16.9, p = 0.532). Individuals with DM2 on insulin scored higher than patients without insulin (27.8 ± 17.6 vs. 18.7 ± 8.5, p = 0.004). Additionally, people with DM1 treated with a system for continuous glucose monitoring (n = 50, 33.1 ± 18.8) scored higher than participants without such system (n = 32, 20.6 ± 13.3, p = 0.001). HbA1c was not correlated with the PAID score in both, DM1 (r = 0.040, p = 0.684) and DM2 (r = − 0.024, p = 0.804). Participants with DM2 and severe hypoglycaemia/last 12 months scored higher than people without (PAID score 43.0 ± 20.4 vs. 25.1 ± 16.5, p = 0.026). Frequency of non-severe hypoglycaemia was not associated with the PAID score in DM1 and DM2. Conclusions: Patients with diabetes treated in hospital for problems with diabetes suffer frequently from diabetes-related distress (~ 24%) regardless of diabetes type.